Overall, these findings imply that PCIF1's enzymatic activity may play a crucial role in the aggressive features of OSCC, highlighting its potential as a target for therapeutic strategies that aim to disrupt m6Am methylation in cancer cells. This evidence concerns the gene PCIF1 and cancer.